Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Pharmacyclics.

    Client Virtual Booth

    PHARMACYCLICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pharmacyclics VB RM
    Pharmacyclics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    999 East Arques AvenueSunnyvale, California 94085
    Telephone
    Telephone
    +1 408-774-0330
    Client Email
    Email
    abbviecontractmfg@abbvie.com
    Client Website
    Website
    https://www.pharmacyclics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pharmacyclics
    Twitter
    Twitter
    https://twitter.com/Pharmacyclics
    Contact Info
    Others

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Appr...

    Details:

    Imbruvica (ibrutinib) is the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, which is indicated for the treatment of chronic lymphocytic leukemia, Waldenström's macroglobulinemia & chronic graft versus host disease.


    Lead Product(s): Ibrutinib

    Therapeutic Area: Oncology Product Name: Imbruvica

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 26, 2024

    Abbvie company banner

    Cophex 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SYMPATICO Trial of Ibrutinib Plus Venetoclax Boosts PFS in MCL

    Details:

    Imbruvica (ibrutinib) is a USFDA approved Bruton’s tyrosine kinase inhibitor. It is being evaluated in combination with venetoclax for the treatment of relapsed/refractory mantle cell lymphoma.


    Lead Product(s): Ibrutinib,Venetoclax

    Therapeutic Area: Oncology Product Name: Imbruvica

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 29, 2024

    Abbvie company banner

    Cophex 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Promising Data in CLL With Ibrutinib/Venetoclax Doublet

    Details:

    Imbruvica (ibrutinib) is a USFDA approved Bruton’s tyrosine kinase inhibitor. It is being evaluated in combination with venetoclax for the treatment of chronic lymphocytic leukemia.


    Lead Product(s): Ibrutinib,Venetoclax

    Therapeutic Area: Oncology Product Name: Imbruvica

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 22, 2024

    Abbvie company banner

    Cophex 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustain...

    Details:

    IMBRUVICA® having Ibrutinib, blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread.


    Lead Product(s): Ibrutinib,Venetoclax

    Therapeutic Area: Oncology Product Name: Imbruvica

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Johnson & Johnson Innovative Medicine

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 10, 2022

    Abbvie company banner

    Cophex 2024

    Not Confirmed

    envelop Contact Supplier
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease

    Details:

    IMB­RUVICA® (ibrutinib) is a once-daily oral medication blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread.


    Lead Product(s): Ibrutinib

    Therapeutic Area: Immunology Product Name: Imbruvica

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Johnson & Johnson Innovative Medicine

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 24, 2022

    Abbvie company banner

    Cophex 2024

    Not Confirmed

    envelop Contact Supplier
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL

    Details:

    Under the terms of the collaboration, the supply of ibrutinib will support the company’s global registrational Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL), ZILO-301.


    Lead Product(s): Zilovertamab,Ibrutinib

    Therapeutic Area: Oncology Product Name: UC961

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Recipient: Oncternal Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration July 14, 2022

    Abbvie company banner

    Cophex 2024

    Not Confirmed

    envelop Contact Supplier
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Access Website

    Contact Supplier

    View Presentation

    Pharmacyclics VB RM

    Chinaplas 2024

    Not Confirmed

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search